Few reports on the effect of antiangiogenic therapy on KRAS-mutant lung cancer indicated that, compared with chemotherapy, the addition of Bevacizumab seemed to have an adverse treatment response [28,29]. This evidence concerns the gene KRAS and lung cancer.